In-Vitro Diagnostics & POC

LamdaGen’s nano-based Plasmonic Diagnostic Platforms enable central laboratory grade quantitation for high-sensitivity immunoassays. The platforms facilitate rapid diagnostic detection limits into the femtomolar range, more than four orders of magnitude lower than that of conventional ELISA.

LamdaGen’s nano-plasmonic LSPR films can be grown on virtually any solid support including:

  • Polymers
  • Flexible Membranes
  • Glass
  • Cellulose
  • Stainless Steel
  • Others…

The Company’s plasmonic sensors are easily manufactured in any size or shape and are typically grown as individual or multi-paneled circular spots ranging in diameter from 300 microns up to 2.5 millimeters each – depending on functional density and system needs.

When coupling flexible sizing with the ability to configure sensors into any shape and upon any solid support – the diagnostic platform becomes an exceedingly adaptable and powerful system for In Vitro Diagnostic integration.  Additionally, the platform offers significant multiplexing capabilities.

The multi-panel LSPR sensors can be configured to meet almost any throughput need – from multi-parallel simultaneous systems to combined multiplexed series formats that can be actively timed or sequenced over periods of minutes, hours or even days – depending on system and end user needs.

LamdaGen’s P8 biosensor used in Plasmonic ELISA for serial dilutions of  C-Reactive Protein (CRP).

LSPR wearable sensing biosensors

LamdaGen’s Plasmonic Biosensors are well suited for integration into wearable diagnostic technologies or devices. For more information, contact


LamdaGen’s Plasmonic-based Diagnostic Platforms enable:

  • Central lab and POC applications
  • Femtomolar sensitivities
  • Precise quantitation
  • Twenty minute assay times
  • Multiplex panels
  • Ideal for wearable and mobile sensing applications

The Platforms provide rapid, laboratory grade sensitivity and specificity, on a range of sample types including:

  • Blood
  • Serum
  • Saliva
  • Urine
  • Tears

LamdaGen has developed very rapid diagnostic assays demonstrating clinical level feasibility in areas such as:

  • Cardiovascular Health
  • Infectious Disease
  • Cancer Biomarkers
  • Drugs of Abuse
  • Veterinary
  • Contaminant Monitoring

For data and additional information, email us at


LamdaGen’s powerful LSPR biosensors manufactured on a 48 spot stainless substrate for throughput.



Troponin I (cTnI) Quantification
A sensitive biomarker of myocardial injury


Troponin I (cTnI):

  • Central to the earlier diagnosis of myocardial infarction (MI)
  • Prediction of outcome: death/MI and further risk

Plasmonic ELISA™ Platform Assay:

  • Detect TnI at 0.64 pg/mL
  • Significantly more sensitive than commercial ELISA kits
  • Precise and easy quantitation


LamdaGen’s nano-based LSPR Plasmonic ELISA typically exceeds conventional ELSIA LOD by more than  four orders.